Article Text

PDF
Buflomedil reduced cardiovascular events in peripheral arterial disease

Statistics from Altmetric.com

A Leizorovicz

Dr A Leizorovicz, Service de Pharmacologie Clinique, Lyon, France; al@upcl.univ-lyon1.fr

STUDY DESIGN

Design:

randomised placebo controlled trial (Limbs International Medicinal Buflomedil [LIMB]).

Allocation:

concealed.*

Blinding:

blinded (patients and outcome assessors).*

STUDY QUESTION

Setting:

123 centres in the Czech Republic, France, Hungary, and Russia.

Patients:

2078 patients who were 40–90 years of age (median age 61 y, 80% men) and had documented peripheral arterial obstructive disease (PAD) and an ankle-brachial index at rest >0.30 and ⩽0.80. Exclusion criteria were ischaemic rest pain, ulceration or gangrene, iliac or common femoral artery stenosis or occlusion, arterial occlusion of embolic origin, Buerger disease or any non-atherosclerotic arterial disease of …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.